159 related articles for article (PubMed ID: 29728868)
1. Curcumin in Advancing Treatment for Gynecological Cancers with Developed Drug- and Radiotherapy-Associated Resistance.
Momtazi-Borojeni AA; Mosafer J; Nikfar B; Ekhlasi-Hundrieser M; Chaichian S; Mehdizadehkashi A; Vaezi A
Rev Physiol Biochem Pharmacol; 2019; 176():107-129. PubMed ID: 29728868
[TBL] [Abstract][Full Text] [Related]
2. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.
Ali AY; Kim JY; Pelletier JF; Vanderhyden BC; Bachvarov DR; Tsang BK
Mol Carcinog; 2015 Nov; 54(11):1301-14. PubMed ID: 25154814
[TBL] [Abstract][Full Text] [Related]
3. Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer.
Zhang J; Liu J; Xu X; Li L
Cancer Chemother Pharmacol; 2017 Mar; 79(3):479-487. PubMed ID: 28175963
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic role of curcumin and its novel formulations in gynecological cancers.
Pourhanifeh MH; Darvish M; Tabatabaeian J; Fard MR; Mottaghi R; Azadchehr MJ; Jahanshahi M; Sahebkar A; Mirzaei H
J Ovarian Res; 2020 Nov; 13(1):130. PubMed ID: 33148295
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers.
Gawde KA; Sau S; Tatiparti K; Kashaw SK; Mehrmohammadi M; Azmi AS; Iyer AK
Colloids Surf B Biointerfaces; 2018 Jul; 167():8-19. PubMed ID: 29625422
[TBL] [Abstract][Full Text] [Related]
6. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs.
Goel A; Aggarwal BB
Nutr Cancer; 2010; 62(7):919-30. PubMed ID: 20924967
[TBL] [Abstract][Full Text] [Related]
7. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer.
Sreekanth CN; Bava SV; Sreekumar E; Anto RJ
Oncogene; 2011 Jul; 30(28):3139-52. PubMed ID: 21317920
[TBL] [Abstract][Full Text] [Related]
8. Potential cytotoxic and anti-metastatic effects of berberine on gynaecological cancers with drug-associated resistance.
Mortazavi H; Nikfar B; Esmaeili SA; Rafieenia F; Saburi E; Chaichian S; Heidari Gorji MA; Momtazi-Borojeni AA
Eur J Med Chem; 2020 Feb; 187():111951. PubMed ID: 31821990
[TBL] [Abstract][Full Text] [Related]
9. Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling.
Fetoni AR; Paciello F; Mezzogori D; Rolesi R; Eramo SL; Paludetti G; Troiani D
Br J Cancer; 2015 Nov; 113(10):1434-44. PubMed ID: 26469832
[TBL] [Abstract][Full Text] [Related]
10. Polyphenol nanoformulations for cancer therapy: experimental evidence and clinical perspective.
Davatgaran-Taghipour Y; Masoomzadeh S; Farzaei MH; Bahramsoltani R; Karimi-Soureh Z; Rahimi R; Abdollahi M
Int J Nanomedicine; 2017; 12():2689-2702. PubMed ID: 28435252
[TBL] [Abstract][Full Text] [Related]
11. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials.
Shehzad A; Wahid F; Lee YS
Arch Pharm (Weinheim); 2010 Sep; 343(9):489-99. PubMed ID: 20726007
[TBL] [Abstract][Full Text] [Related]
12. Molecular Mechanisms of Anti-metastatic Activity of Curcumin.
Deng YI; Verron E; Rohanizadeh R
Anticancer Res; 2016 Nov; 36(11):5639-5647. PubMed ID: 27793885
[TBL] [Abstract][Full Text] [Related]
13. Preclinical studies for the combination of paclitaxel and curcumin in cancer therapy (Review).
Wei Y; Pu X; Zhao L
Oncol Rep; 2017 Jun; 37(6):3159-3166. PubMed ID: 28440434
[TBL] [Abstract][Full Text] [Related]
14. The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer.
Heger M; van Golen RF; Broekgaarden M; Michel MC
Pharmacol Rev; 2014; 66(1):222-307. PubMed ID: 24368738
[TBL] [Abstract][Full Text] [Related]
15. Combinatorial Effects of Curcumin with an Anti-Neoplastic Agent on Head and Neck Squamous Cell Carcinoma Through the Regulation of EGFR-ERK1/2 and Apoptotic Signaling Pathways.
Sivanantham B; Sethuraman S; Krishnan UM
ACS Comb Sci; 2016 Jan; 18(1):22-35. PubMed ID: 26505786
[TBL] [Abstract][Full Text] [Related]
16. Curcumin in various cancers.
Shehzad A; Lee J; Lee YS
Biofactors; 2013; 39(1):56-68. PubMed ID: 23303705
[TBL] [Abstract][Full Text] [Related]
17. Curcumin: A potentially powerful tool to reverse cisplatin-induced toxicity.
Rezaee R; Momtazi AA; Monemi A; Sahebkar A
Pharmacol Res; 2017 Mar; 117():218-227. PubMed ID: 28042086
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents.
Chan MM; Fong D; Soprano KJ; Holmes WF; Heverling H
J Cell Physiol; 2003 Jan; 194(1):63-70. PubMed ID: 12447990
[TBL] [Abstract][Full Text] [Related]
20. Curcumin-Based Nanoformulations: A Promising Adjuvant towards Cancer Treatment.
Hafez Ghoran S; Calcaterra A; Abbasi M; Taktaz F; Nieselt K; Babaei E
Molecules; 2022 Aug; 27(16):. PubMed ID: 36014474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
